Literature DB >> 20473243

Biomarker discovery and development in pediatric critical care medicine.

Jennifer M Kaplan1, Hector R Wong.   

Abstract

OBJECTIVES: To frame the general process of biomarker discovery and development; and to describe a proposal for the development of a multibiomarker-based risk model for pediatric septic shock. DATA SOURCE: Narrative literature review and author-generated data. DATA SELECTION: Biomarkers can be grouped into four broad classes, based on the intended function: diagnostic, monitoring, surrogate, and stratification. DATA EXTRACTION AND SYNTHESIS: Biomarker discovery and development requires a rigorous process, which is frequently not well followed in the critical care medicine literature. Very few biomarkers have successfully transitioned from the candidate stage to the true biomarker stage. There is great interest in developing diagnostic and stratification biomarkers for sepsis. Procalcitonin is currently the most promising diagnostic biomarker for sepsis. Recent evidence suggested that interleukin-8 can be used to stratify children with septic shock having a high likelihood of survival with standard care. Currently, there is a multi-institutional effort to develop a multibiomarker-based sepsis risk model intended to predict outcome and illness severity for individual children with septic shock.
CONCLUSIONS: Biomarker discovery and development are an important portion of the pediatric critical care medicine translational research agenda. This effort will require collaboration across multiple institutions and investigators. Rigorous conduct of biomarker-focused research holds the promise of transforming our ability to care for individual patients and our ability to conduct clinical trials in a more effective manner.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20473243      PMCID: PMC2924462          DOI: 10.1097/PCC.0b013e3181e28876

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  61 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis.

Authors:  B Müller; J C White; E S Nylén; R H Snider; K L Becker; J F Habener
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

Review 3.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors:  Nader Rifai; Michael A Gillette; Steven A Carr
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

4.  Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin.

Authors:  F M Brunkhorst; O K Eberhard; R Brunkhorst
Journal:  Crit Care Med       Date:  1999-10       Impact factor: 7.598

Review 5.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis.

Authors:  Bernard Uzzan; Régis Cohen; Patrick Nicolas; Michel Cucherat; Gérard-Yves Perret
Journal:  Crit Care Med       Date:  2006-07       Impact factor: 7.598

6.  Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery.

Authors:  C R Parikh; J Mishra; H Thiessen-Philbrook; B Dursun; Q Ma; C Kelly; C Dent; P Devarajan; C L Edelstein
Journal:  Kidney Int       Date:  2006-05-17       Impact factor: 10.612

7.  Extracellular hsp70 levels in children with septic shock.

Authors:  Derek S Wheeler; Lyle E Fisher; John D Catravas; Brian R Jacobs; Joseph A Carcillo; Hector R Wong
Journal:  Pediatr Crit Care Med       Date:  2005-05       Impact factor: 3.624

8.  Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.

Authors:  Paul M Ridker; David A Morrow; Lynda M Rose; Nader Rifai; Christopher P Cannon; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2005-04-25       Impact factor: 24.094

9.  Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children.

Authors:  A Enguix; C Rey; A Concha; A Medina; D Coto; M A Diéguez
Journal:  Intensive Care Med       Date:  2001-01       Impact factor: 17.440

Review 10.  Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis.

Authors:  Sven K Tschoeke; Andreas Oberholzer; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2006-04       Impact factor: 7.598

View more
  39 in total

1.  Prognostic markers for pediatric septic shock: which ones, when, and how?

Authors:  Corsino Rey; James D Fortenberry
Journal:  Intensive Care Med       Date:  2013-07-31       Impact factor: 17.440

Review 2.  The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology.

Authors:  Matthew N Alder; Christopher J Lindsell; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2014-04-22       Impact factor: 5.091

Review 3.  Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment.

Authors:  Mary Sandquist; Hector R Wong
Journal:  Expert Rev Clin Immunol       Date:  2014-08-21       Impact factor: 4.473

Review 4.  Emerging infection and sepsis biomarkers: will they change current therapies?

Authors:  Lauren Jacobs; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08-17       Impact factor: 5.091

5.  A multibiomarker-based outcome risk stratification model for adult septic shock*.

Authors:  Hector R Wong; Christopher J Lindsell; Ville Pettilä; Nuala J Meyer; Simone A Thair; Sari Karlsson; James A Russell; Christopher D Fjell; John H Boyd; Esko Ruokonen; Michael G S Shashaty; Jason D Christie; Kimberly W Hart; Patrick Lahni; Keith R Walley
Journal:  Crit Care Med       Date:  2014-04       Impact factor: 7.598

Review 6.  Monitoring Severity of Multiple Organ Dysfunction Syndrome: New Technologies.

Authors:  Katri V Typpo; Hector R Wong; Stacey D Finley; Rodney C Daniels; Andrew J E Seely; Jacques Lacroix
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

Review 7.  Pediatric sepsis: challenges and adjunctive therapies.

Authors:  William Hanna; Hector R Wong
Journal:  Crit Care Clin       Date:  2013-01-03       Impact factor: 3.598

Review 8.  Gene expression profiling in sepsis: timing, tissue, and translational considerations.

Authors:  David M Maslove; Hector R Wong
Journal:  Trends Mol Med       Date:  2014-02-15       Impact factor: 11.951

9.  An Enrichment Strategy For Sepsis Clinical Trials.

Authors:  Hector R Wong; Christopher J Lindsell
Journal:  Shock       Date:  2016-12       Impact factor: 3.454

Review 10.  Sepsis in Pediatric Cardiac Intensive Care.

Authors:  Derek S Wheeler; Hector R Wong
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.